18-Methoxycoronaridine
Overview
(-)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine and nicotine.[1] 18MC is a selective α3β4 nicotinic antagonist and, opposed to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter.[2] There is no publication that would indicate that it had ever been tested in humans.
References
- ↑ S.D. Glick (1996). “18-Methoxycoronaridine, a non-toxic iboga alkaloid congener:
effects on morphine and cocaine self-administration and on mesolimbic
dopamine release in rats”. Brain Res. 719 (1–2): 29–35. PMID 8782860. line feed character in
|title=at position 61 (help) - ↑ I.M. Maisonneuve (2003). “Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment”. Pharmacol. Biochem. Behav. 75 (3): 607–18. PMID 12895678.
Further reading
- S.D. Glick (2006). “18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats”. Eur. J. Pharmacol. PMID 16626688.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH